Check Out The COVID-19 Herbs and COVID-19 Supplements Sections Under The Drop Down Menu Of Trending Topics On The Main Menu Bar

BREAKING NEWS
Source: COVID-19 Bradykinin Storms  Sep 03, 2020  3 months ago
COVID-19 ‘Bradykinin Storm’ Hypothesis Gaining Stronghold Among Medical Community And Offers New Avenues For Treatments Using Already-Approved Drugs
COVID-19 ‘Bradykinin Storm’ Hypothesis Gaining Stronghold Among Medical Community And Offers New Avenues For Treatments Using Already-Approved Drugs
Source: COVID-19 Bradykinin Storms  Sep 03, 2020  3 months ago
By detailed analysis of data on more than 40,000 genes , 17,000 genetic  and 2.5 billion genetic combinations samples linked to COVID-19, researchers from Oak Ridge National Lab in Tennessee have managed by using the world’s second fastest computer called the Summit supercomputer have come up with a hypothesis as to how the SARS-CoV-2 coronavirus affects the human host dubbed the “Bradykinin Storm Hypothesis.”


 
The research findings are published in the journal: eLife. https://elifesciences.org/articles/59177
 
Computational systems biologist at Oak Ridge, Daniel Jacobson and his research team noted that the expression of genes for significant enzymes in the renin-angiotensin system (RAS), which is involved in blood pressure regulation and fluid balance, was abnormal.
 
The study team then tracked the abnormal RAS in the lung fluid samples to the kinin cascade, which is an inflammatory pathway closely regulated by the RAS.
 
Typically in the In the kinin pathway, bradykinin, which is a key peptide, causes blood vessels to leak, allowing fluid to accumulate in organs and tissue. And in COVID-19 patients, this system was unbalanced. People with the disease had increased gene expression for the bradykinin receptors and for enzymes known as kallikreins that activate the kinin pathway.
 
The study team believe that this research explains many aspects of COVID-19 that were previously not understood, including why there is an abnormal accumulation of fluid in the patients’ lungs.
 
Based on their research findings, SARS-CoV-2 infection typically starts when the virus enters the body via ACE2 receptor in the nose, where they are common. The virus then moves through the body, integrating into cells that also have ACE2, including the intestines, kidneys and heart. This is consistent with some of COVID-19’s cardiac and gastrointestinal symptoms.
 
However the SARS-CoV-2 coronavirus virus does not appear to stop there. Instead, it takes over the body’s systems, upregulating ACE2 receptors in cells and tissues where they’re not common, including the lungs.
 
The study team said, “COVID-19 is like a burglar who slips in your unlocked second-floor window and starts to ransack your house. Once inside, though, they don’t just take your stuff, they also throw open all your doors and windows so their accomplices can rush in and help pillage more efficiently.”
 
The resultant and final condition is what the study team terms as a bradykinin storm. When the coronavirus affects the RAS, the way the body that normally regulates bradykinin runs amuck, bradykinin receptors are resensitized, and the body stops breaking down bradykinin, which is typically degraded by ACE.
 
The team says that it is this bradykinin storm that is responsible for many of COVID-19’s deadliest symptoms.
 
The study team wrote that “the pathology of COVID-19 is likely the result of Bradykinin Storms rather than cytokine storms,” which have been observed in COVID-19 patients, but that “the two may be intricately linked.”
 
Leading expert, Dr Frank van de Veerdonk, an infectious disease researcher at the Radboud University Medical Center in Netherlands, had made similar observations in mid-March. In April, he and his research team theorized that a dysregulated bradykinin system was causing leaky blood vessels in the lungs, which was a potential cause of the excess fluid accumulation. https://www.preprints.org/manuscript/202004.0023/v1
 
Dr Josef Penninger, director of the Life Sciences Institute at the University of British Columbia in Vancouver, who identified that ACE2 is the essential in vivo receptor for SARS, alsobelieves bradykinin plays a role in COVID-19. He said, “It does make a lot of sense. And Jacobson’s study supports the hypothesis, but additional research is needed for confirmation. Gene expression signatures don’t tell us the whole story. I think it is very important to actually measure the proteins.”
 
Significantly another aspect of Jacobson’s study is that via another pathway, COVID-19 increases production of hyaluronic acid (HLA) in the lungs. HLA is common in soaps and lotions because it absorbs more than 1,000 times its weight in fluid. Taking into consideration fluid leaking into the lungs and increased HLA, it creates a hydrogel in the lungs of some COVID-19 patients, which Jacobson describes as “like trying to breathe through Jell-O.”
 
Experts are now saying that this provides a possible explanation for why ventilators have been less effective in severe COVID-19 than physicians originally expected.
 
Jacobson commented, “It reaches a point where regardless of how much oxygen you pump in, it doesn’t matter, because the alveoli in the lungs are filled with this hydrogel. The lungs become like a water balloon.”
 
The new ‘bradykinin storm’ hypothesis also explains why about 20% of COVID-19 patients have heart damage, because RAS controls aspects of cardiac contractions and blood pressure. It also supports COVID-19’s neurological effects, such as dizziness, seizures, delirium and stroke, which is seen in as much as 50% of hospitalized patients. French-based research identified leaky blood vessels in the brains of COVID-19 patients. And at high doses, bradykinin can break down the blood-brain barrier.
 
The study team also suggests that drugs that target components of RAS are already FDA approved for other diseases and might be effective in treating COVID-19.
 
The study team said that possible identified drug candidates that could be repurposed based on further research include danazol (to treat endometriosis, fibrocystic breast disease, and hereditary angioedema), stanazolol (an anabolic steroid derived from testosterone), and ecallantide (marketed as Kalbitor for hereditary angioedema (HAE) and the prevention of blood loss in cardiothoracic surgery), decrease bradykinin production. Icatibant, also used to treat HAE, and is marketed as Firazyr, decreases bradykinin signaling and could minimize its effects once it’s in the body.
 
The study team also said that Vitamin D may potentially be useful, because it is involved in the RAS system and may reduce levels of REN, another compound involved in the system. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893307/#:~:text=Disruption%20of%20vitamin%20D%20signaling,and%20blood%20pressure%20(BP). and
 
 https://pubmed.ncbi.nlm.nih.gov/22075270/ and
 
https://www.hindawi.com/journals/bmri/2015/145828/ and
 
https://www.ahajournals.org/doi/full/10.1161/hypertensionaha.109.148619 and

https://www.metabolismjournal.com/article/S0026-0495(11)00303-9/pdf
 
The study team note that “the testing of any of these pharmaceutical interventions should be done in well-designed clinical trials.”
 
For more about COVID-19 Bradykinin Storms, keep on Logging to Thailand Medical News.
 


 

MOST READ

Source: Supplements For COVID-19
Aug 13, 2020  4 months ago
Source : Thailand Medical news
Feb 05, 2020  10 months ago